Continuing Education

Background: The Reduction of Cardiovascular Events with Icosapent Ethyl (IE)-Intervention Trial (REDUCE-IT) demonstrated the efficacy of IE among patients with

Heart failure is a leading diagnosis for hospitalization with a high risk of readmission. Despite robust data and recommendations by

Introduction: Congenital heart defects (CHD) are the most common birth defects and are estimated to affect almost 1% of births

Global longitudinal strain (GLS) analysis via speckle tracking echocardiography is a relatively new and promising imaging technology for the assessment

Background: Impact of social isolation associated with the COVID-19 pandemic on the severity and frequency of cardiac symptoms has not

Background: Cholesterol treatment is central to cardiovascular risk reduction, but disparities in management may exist. Our hypothesis is that demographic

Background: Outcomes in heart failure with reduced ejection fraction (HFrEF), are influenced by access and adherence to guideline-directed medical therapy.

Background: Baseline physical activity in patients when they initiate cardiac rehabilitation is poorly understood. We used mobile health (mHealth) technology

Background: Despite reported benefit in the setting of aortic valve replacement (AVR), cardiac rehabilitation (CR) utilization remains low, with few

Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. Source link